Once-weekly efsitora shows hospitalization outcomes similar to daily basal insulin

This pooled post hoc analysis gives pharmacists early reassurance that once-weekly insulin efsitora alfa behaves like daily basal insulin around hospitalization, while flagging a higher treatment discontinuation signal in hospitalized patients.

📅 Journal publication: Oct 3, 2026 · Last updated: Oct 12, 2026

insulin efsitora alfaonce-weekly insulininsulin glargineinsulin degludecbasal insulintype 2 diabetes mellitushospitalizationhypoglycemiaQWINTpost hoc analysisEndocrinology Endocrinology / Diabetes / Obesity

Background Information

Once-weekly insulin shows promising hospitalization outcomes in type 2 diabetes.

Insulin dosing frequency can impact adherence and hospitalization rates in patients with type 2 diabetes mellitus. The analysis found that once-weekly insulin efsitora achieved similar hospitalization outcomes compared to daily basal insulins. Findings suggest that once-weekly insulin may be a viable alternative to daily injections, but more direct comparisons are needed. Once-weekly insulin efsitora may reduce dosing burden with comparable hospitalization outcomes.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Philis-Tsimikas A, Galindo RJ, Guerci B, Threlkeld RJ, Mushala B, Shyam CP, Goldyn A

Citation: Philis-Tsimikas A, Galindo RJ, Guerci B, et al. Hospitalization outcomes in adults with type 2 diabetes mellitus treated with once-weekly insulin efsitora versus once-daily basal insulins: A post hoc analysis of the QWINT-1 to -4 randomized trials. Diabetes research and clinical practice. 2026:113586. doi:10.1016/j.diabres.2026.113586

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →